-- Advanced Radiofrequency Treatment Improves Local Circulation
in Vaginal Tissue --
MARLBOROUGH, Mass.,
July 11, 2018 /PRNewswire/ --
Hologic's (Nasdaq: HOLX) Cynosure division announced today the
North American launch of TempSure™ Vitalia, an
FDA-cleared and Health Canada-approved advanced radiofrequency
treatment. Birth control, pregnancy, hormones, and aging can change
the condition of vaginal tissue over time. TempSure™
Vitalia delivers therapeutic heat to internal and external vaginal
tissue to improve local circulation.
The TempSure™ Vitalia treatment, administered using
a probe specifically designed for women's genitalia, delivers
precise heating for smaller, hard-to-reach areas such as vaginal
and labial tissue, without hormones or the need for invasive
procedures. Treatments can last between 15 and 30 minutes,
depending on the treatment area, and there's no downtime once the
procedure is complete.
Unlike other radiofrequency devices, TempSure™
Vitalia has the distinct advantage of Therapeutic Logic Control
(TLC) – a revolutionary time and temperature monitoring system that
ensures treatment timing will begin only when the target tissue is
at therapeutic temperature, helping deliver repeatable treatment
results procedure after procedure. The device also has a unique
dose counter that monitors and effectively delivers the recommended
dose of radiofrequency energy to the target area.
"TempSure Vitalia responds to customers who expressed a need for
a consistent and effective intimate wellness therapy that takes the
guesswork out of radiofrequency treatments," said Kevin Thornal, Hologic's Division President,
Cynosure. "It also expands the offerings on our TempSure
radiofrequency platform. We are pleased that in just six months, we
were able to launch an additional handpiece while simultaneously
providing a solution to patients who have experienced changes in
their vaginal health over time."
In January 2018, Cynosure launched
the TempSure™ platform with TempSure™
Envi, a device for minimizing fine facial lines and wrinkles,
tightening the skin through soft tissue coagulation, and improving
the appearance of cellulite.
To learn more about TempSure™ Vitalia, please visit
https://www.cynosure.com/product/tempsure-vitalia/.
About Hologic, Inc.
Hologic, Inc. is an innovative
medical technology company primarily focused on improving women's
health and well-being through early detection and treatment. For
more information on Hologic, visit www.hologic.com.
Hologic, The Science of Sure, Cynosure and TempSure are
trademarks and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States
and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated
in any particular manner with respect to an individual patient, as
the actual effect of the use of the products can only be determined
on a case-by-case basis. In addition, there can be no assurance
that these products will be commercially successful or achieve any
expected level of sales. Hologic expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such data or statements are based.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
858.410.8588
michael.watts@hologic.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/hologics-cynosure-division-launches-tempsure-vitalia-in-north-america-300678875.html
SOURCE Hologic, Inc.